Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia. Levels of FGF23 and Sclerostin in COVID-19 patients will be detected and correlated to calcium levels.
COVID 19 is a current worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 "SARS-CoV-2". Hypovitaminosis D and hypocalcaemia have been reported to be associated with COVID 19 infection, they are considered good biomarkers of clinical severity of COVID 19. Poor prognosis related to hypocalcemia is increased in elderly patients. Fibroblast growth factor 23 and sclerostin are secreted from the bone, they decrease active vitamin D levels. Their levels and their relation to calcium levels in COVID-19 patients will be detected.
Study Type
OBSERVATIONAL
Enrollment
66
Free calcium serum levels
Serum level
Serum level
Aswan University hospital
Aswān, Egypt
Changes in serum calcium levels
Expected lower serum calcium levels in COVID 19 patients compared to control
Time frame: 6 months
changes in FGF23 levels
Expected higher FGF23 levels in COVID 19 patients compared to control
Time frame: 6 months
changes in sclerostin levels
Expected higher sclerostin levels in COVID 19 patients compared to control
Time frame: 6 months
Changes in parathyroid hormone levels
Expected lower levels in COVID 19 patients compared to control
Time frame: 6 months
Relation between FGF 23 and calcium levels
A negative relation is expected
Time frame: 6 months
Relation between sclerostin and calcium levels
A negative relation is expected
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
serum level